格瑞农生物完成近亿元Pre-B轮融资，加速噬菌体产业布局

Core Viewpoint - The article highlights the significant advancements of Wuhan Grey Agricultural Biotechnology Co., Ltd. (Grey Agricultural) in the phage therapy industry, including its recent Pre-B round financing and its status as the first company globally to obtain GMP certification for phage preparations [3][5]. Financing and Investment - Grey Agricultural has completed nearly 100 million yuan in Pre-B round financing, led by Guoxin Hongsheng and followed by Taiyu Investment, with Kaicheng Capital serving as the long-term exclusive financial advisor [3]. - The financing will primarily be used for the development of an AI platform, engineering phages, phage peptides/lytic enzymes, and market expansion in various applications such as animal health, plant protection, and food safety [3]. Application Scenarios - The company is expanding its phage technology from animal health and plant protection to broader applications in food safety and consumer healthcare [4]. - In food safety, Grey Agricultural is developing new biological preservation and contamination control solutions targeting key pathogens like E. coli, Salmonella, Listeria, and Campylobacter, particularly in cold chain and meat products [4]. - In consumer healthcare, the company is focusing on products for skin barrier damage, oral care, and chronic wound management, providing alternatives in the transition from the "antibiotic era" to the "precision microbial control era" [4]. Regulatory Milestones - With the European Medicines Agency (EMA) releasing the first quality guidelines for phage therapy drugs, Grey Agricultural has established a GMP-compliant production system, becoming the first company globally to achieve GMP certification for phage preparations [5]. - The company has aligned its processes with international standards in seed batch systems, host library management, whole-genome quality control, and process validation, positioning itself favorably for future cross-border collaborations and global supply chain integration [5]. Strategic Vision - The founder of Grey Agricultural expressed gratitude for the support from investors and emphasized the company's commitment to deepening research in engineering phages and phage peptides/lytic enzymes, aiming for product implementation and market penetration across multiple scenarios [5]. - Investors have expressed confidence in Grey Agricultural's systematic layout and solid accumulation in the phage field, anticipating accelerated progress in new veterinary drug approvals and expansion into plant protection and consumer healthcare [5][6].